Publications

  Update: 08 January 2021 No update available.   Update: 05 November 2020 Researchers at the University of California – San Francisco (UCSF) are conducting a Phase I clinical trial…

Update: 08 January 2021 No update available.   Update: 05 November 2020 The first thalassaemia patient has been dosed in the FORTE clinical trial – a Phase 2b clinical trial…

The second educational brochure from the TIF’s ‘Gene Therapy’ booklet series, providing an in-depth view of how this revolutionary therapy works in patients with β-thalassaemia major.

An educational brochure explaining the inheritance patterns of β-thalassaemia and the choices available for an ”at-risk” couple to have a child without the disease.

This document, prepared by the Thalassaemia International Federation , is a compilation of information exclusively for Sickle Cell Disease patients with regard to the coronavirus pandemic.

A TIF-compiled document aiming to provide a division of risk levels for thalassaemia and SCD patients with regards to the ongoing COVID-19 pandemic.

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.

TIF has compiled a list of studies/clinical trials for developing drugs and vaccines for the COVID-19 Pandemic, which is by no means exhaustive as research in this area is dramatically…

An informational guide about blood adequacy and safety during the COVID-19 Pandemic, compiled on the basis of official recommendations from internationally recognized bodies.

A  Haemoglobinopathy Patient Care Pathway suggesting changes to be made during the outbreak of COVID-19 in the admittance of patients to haemoglobinopathy day care centres /units /clinics.